source
- Lilly’s ‘triple-G’ drug tops Novo’s Ozempic in diabetes trialThe highest dose of retatrutide beat Ozempic on measures of blood sugar and weight loss, but was also associated with higher side effect rates and treatment discontinuations.BioPharma Dive · 12d ago↗ source
- Lilly’s retatrutide trounces Novo’s Ozempic in diabetes, weight lossEli Lilly’s next-gen weight loss drug retatrutide soundly beat Novo’s approved medicine Ozempic in weight loss and blood sugar reduction, padding the case for a regulatory application that’s expect…BioSpace · 12d ago↗ source
- Lilly's triple-G drug retatrutide outshines Novo's Ozempic in diabetesEli Lilly’s retatrutide, the incretin shot that has already proven its effectiveness against other assets on a cross-trial basis, has cemented its utility in a head-to-head trial, albeit in diabete…